                         SEQUENCE LISTING

<110>  B. G. Negev Technologies and Applications Ltd., at 
       Ben-Gurion University
 
<120>  PEPTIDE-POLYPEPTIDE CO-ASSEMBLED NANOPARTICLES FOR DRUG DELIVERY

<130>  BGU/034 PCT

<160>  17    

<170>  PatentIn version 3.5

<210>  1
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  1

Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe 
1               5                   10              


<210>  2
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  2

Pro Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Pro 
1               5                   10              


<210>  3
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  3

Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe 
1               5                   10      


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  4

Pro Lys Phe Lys Phe Lys Phe Lys Phe Lys Pro 
1               5                   10      


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  5

Phe Lys Phe Lys Phe Lys Phe Lys Phe 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  6

Pro Lys Phe Lys Phe Lys Phe Lys Pro 
1               5                   


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  7

Phe Lys Phe Lys Phe Lys Phe 
1               5           


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  8

Pro Lys Phe Lys Phe Lys Pro 
1               5           


<210>  9
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  9

Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe 
1               5                   10                  15  


<210>  10
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  10

Pro Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Pro 
1               5                   10                  15  


<210>  11
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  11

Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys 
1               5                   10                  15      


Phe 
    


<210>  12
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  12

Pro Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys 
1               5                   10                  15      


Pro 
    


<210>  13
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  13

Leu Leu Leu Leu Phe Lys Phe Lys Phe Lys Pro 
1               5                   10      


<210>  14
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  14

Leu Leu Leu Leu Leu Phe Lys Phe Lys Phe Lys Pro 
1               5                   10          


<210>  15
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  15

Leu Leu Leu Leu Leu Leu Phe Lys Phe Lys Phe Lys Pro 
1               5                   10              


<210>  16
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  16

Lys Phe Phe Pro Lys Lys Pro Phe Lys Phe Phe Lys Lys 
1               5                   10              


<210>  17
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  17

Lys Phe Phe Phe Lys Lys Phe Phe Lys Phe Phe Lys Lys 
1               5                   10              


